ES2505466T3 - Procedimientos para predecir la respuesta al tratamiento del cáncer de mama triple negativo - Google Patents

Procedimientos para predecir la respuesta al tratamiento del cáncer de mama triple negativo Download PDF

Info

Publication number
ES2505466T3
ES2505466T3 ES11733335.1T ES11733335T ES2505466T3 ES 2505466 T3 ES2505466 T3 ES 2505466T3 ES 11733335 T ES11733335 T ES 11733335T ES 2505466 T3 ES2505466 T3 ES 2505466T3
Authority
ES
Spain
Prior art keywords
breast cancer
response
triple negative
negative breast
predicting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11733335.1T
Other languages
English (en)
Spanish (es)
Inventor
Xinjun Liu
Phillip Kim
Richard Kirkland
Tani Lee
Belen Ybarrondo
Sharat Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Application granted granted Critical
Publication of ES2505466T3 publication Critical patent/ES2505466T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ES11733335.1T 2010-01-12 2011-01-12 Procedimientos para predecir la respuesta al tratamiento del cáncer de mama triple negativo Active ES2505466T3 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US29443310P 2010-01-12 2010-01-12
US294433P 2010-01-12
US32562410P 2010-04-19 2010-04-19
US325624P 2010-04-19
US32860210P 2010-04-27 2010-04-27
US328602P 2010-04-27
US35183810P 2010-06-04 2010-06-04
US351838P 2010-06-04
PCT/US2011/021026 WO2011088149A2 (en) 2010-01-12 2011-01-12 Methods for predicting response of triple-negative breast cancer to therapy

Publications (1)

Publication Number Publication Date
ES2505466T3 true ES2505466T3 (es) 2014-10-10

Family

ID=44304951

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11733335.1T Active ES2505466T3 (es) 2010-01-12 2011-01-12 Procedimientos para predecir la respuesta al tratamiento del cáncer de mama triple negativo

Country Status (15)

Country Link
US (2) US9488654B2 (enExample)
EP (1) EP2524232B1 (enExample)
JP (1) JP5764144B2 (enExample)
KR (1) KR20120115390A (enExample)
CN (1) CN102822676B (enExample)
AU (1) AU2011205343B2 (enExample)
BR (1) BR112012017084A2 (enExample)
CA (1) CA2787225A1 (enExample)
ES (1) ES2505466T3 (enExample)
IL (1) IL220833A0 (enExample)
MX (1) MX2012008153A (enExample)
NZ (1) NZ601348A (enExample)
RU (1) RU2558931C2 (enExample)
WO (1) WO2011088149A2 (enExample)
ZA (1) ZA201206019B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
EP2788752B1 (en) * 2011-12-05 2018-10-03 Pierian Holdings, Inc. Method of therapy selection for patients with lung cancer
CA2862835A1 (en) * 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists
WO2014001232A1 (en) * 2012-06-26 2014-01-03 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
US9422602B2 (en) 2012-08-15 2016-08-23 Bio-Rad Laboratories, Inc. Methods and compositions for determining nucleic acid degradation
WO2014071218A2 (en) * 2012-11-02 2014-05-08 University Of Utah Research Foundation Biomarkers for breast cancer and methods of using same
KR20140096571A (ko) 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
WO2015028974A2 (en) * 2013-08-30 2015-03-05 Nestec S.A. Polyp recurrence
ES2763429T5 (es) * 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
EP3006940A1 (en) * 2014-10-10 2016-04-13 Ruprecht-Karls-Universität Heidelberg Biomarkers for predicting the response to anti-angiogenic cancer therapy
CN105891496A (zh) * 2014-12-09 2016-08-24 上海华盈生物医药科技有限公司 酪氨酸激酶抑制剂类靶向用药指导抗体芯片和检测方法
CN104830775B (zh) * 2015-04-14 2019-06-21 上海中医药大学附属龙华医院 一种三阴性乳腺癌顺铂耐药细胞株及其制备方法和用途
HRP20260689T1 (hr) 2015-06-17 2026-07-17 F. Hoffmann-La Roche Ag Postupci za liječenje lokalno uznapredovalog ili metastatskog raka dojke primjenom antagonista vezivanja osi pd-1 i taksana
US20180303830A1 (en) * 2015-06-22 2018-10-25 Thomas Jefferson University Cancers expressing ccr5 and methods of treatment of same
EP3363911B1 (en) * 2015-10-14 2024-09-25 Nitto Boseki Co., Ltd. Method for determining drug-sensitive human breast cancer cells by analysis method in which measurement of activity of two types of protein kinase is used
RU2616533C1 (ru) * 2016-03-15 2017-04-17 Федеральное государственное бюджетное научное учреждение "Томский научно-исследовательский институт онкологии" (Томский НИИ онкологии) Способ прогнозирования эффективности терапии эверолимусом у больных метастатическим раком почки
IL245861A0 (en) 2016-05-25 2016-09-04 Yeda Res & Dev Use of substances to treat drug-resistant tumors
CN109789204A (zh) * 2016-05-31 2019-05-21 雀巢产品技术援助有限公司 基于her2和her3通路亚型选择乳癌患者药物疗法的方法
CN106645728A (zh) * 2016-11-09 2017-05-10 百奥森（江苏）食品安全科技有限公司 一种食品中氟喹诺酮类药物的检测试剂盒
RU2648523C1 (ru) * 2017-05-22 2018-03-26 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Способ прогнозирования исхода заболевания у больных люминальным в и трижды негативным раком молочной железы у пациенток, не получавших в неоадъювантном режиме химио- или гормонотерапию
CN109470854B (zh) * 2017-09-08 2022-02-11 广州市丹蓝生物科技有限公司 肺癌诊断用蛋白芯片及试剂盒
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
US20210088523A1 (en) * 2019-09-23 2021-03-25 Sri International Methods for detecting circulating tumor cells in non-small cell lung cancer
US11366101B1 (en) 2020-12-31 2022-06-21 Elephas Biosciences Corporation Ex vivo systems and methods for determining the effect of a drug or other agent on a tissue
CN120731084A (zh) * 2023-03-15 2025-09-30 侯明宏 用于治疗三阴性乳癌的药物组合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532138A (en) 1990-04-26 1996-07-02 Behringwerke Ag Method and kits for determining peroxidatively active catalysts
US5332662A (en) 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
WO1995006877A1 (en) 1993-09-03 1995-03-09 Behringwerke Ag Fluorescent oxygen channeling immunoassays
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US6897073B2 (en) 1998-07-14 2005-05-24 Zyomyx, Inc. Non-specific binding resistant protein arrays and methods for making the same
US6780582B1 (en) 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6197599B1 (en) 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing
CA2418105A1 (en) 2000-08-03 2002-02-14 Massachusetts Institute Of Technology Microarrays of functional biomolecules, and uses therefor
AU2002303384A1 (en) 2001-04-17 2002-10-28 William J. Dower Epitope-captured antibody display
US20030153013A1 (en) 2002-11-07 2003-08-14 Ruo-Pan Huang Antibody-based protein array system
US20060263837A1 (en) 2004-06-17 2006-11-23 Liu George D Immunoassay system and method for detection of antigens
CN103169729A (zh) * 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US7771955B2 (en) 2005-06-09 2010-08-10 University Of Maryland Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule
CN104198705B (zh) * 2006-09-21 2017-06-09 雀巢产品技术援助有限公司 检测稀有循环细胞内多种信号转导分子的基于抗体的阵列
RU2341198C2 (ru) * 2006-11-27 2008-12-20 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ оценки ангиогенных факторов при химиотерапии рака молочной железы
EP2109686A2 (en) * 2007-01-18 2009-10-21 University Of Southern California Genetic markers for predicting responsiveness to combination therapy
JP2010540459A (ja) * 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． Ｃｏｘ‐２阻害薬及びｅｇｆｒ［ｅｒｂｂ１］とｈｅｒ‐２［ｅｒｂｂ２］の二重阻害薬を用いた癌を治療するための併用療法
ES2553390T3 (es) * 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
US8071315B2 (en) * 2008-04-30 2011-12-06 Sanford-Burnham Medical Research Institute Detecting Bcl-B expression in cancer and uses thereof
NZ596468A (en) 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
CA2804350A1 (en) * 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Also Published As

Publication number Publication date
KR20120115390A (ko) 2012-10-17
AU2011205343A1 (en) 2012-08-02
US10697967B2 (en) 2020-06-30
US9488654B2 (en) 2016-11-08
JP5764144B2 (ja) 2015-08-12
ZA201206019B (en) 2015-06-24
WO2011088149A3 (en) 2011-10-27
CN102822676B (zh) 2015-02-18
RU2558931C2 (ru) 2015-08-10
AU2011205343B2 (en) 2015-08-13
MX2012008153A (es) 2012-11-06
BR112012017084A2 (pt) 2016-04-12
CN102822676A (zh) 2012-12-12
EP2524232A2 (en) 2012-11-21
EP2524232A4 (en) 2013-06-12
HK1178602A1 (en) 2013-09-13
US20130012407A1 (en) 2013-01-10
US20170227542A1 (en) 2017-08-10
WO2011088149A2 (en) 2011-07-21
IL220833A0 (en) 2012-08-30
CA2787225A1 (en) 2011-07-21
EP2524232B1 (en) 2014-08-06
JP2013517461A (ja) 2013-05-16
RU2012134390A (ru) 2014-02-20
NZ601348A (en) 2014-07-25

Similar Documents

Publication Publication Date Title
Muratori et al. Myxoid liposarcoma: prognostic factors and metastatic pattern in a series of 148 patients treated at a single institution
Harvey et al. Survival outcomes for stage‐matched endoscopic and open resection of olfactory neuroblastoma
Proctor et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study
Almangush et al. Depth of invasion, tumor budding, and worst pattern of invasion: prognostic indicators in early‐stage oral tongue cancer
Duchnowska et al. Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain
Ding et al. A proposal for combination of lymph node ratio and anatomic location of involved lymph nodes for nodal classification in non–small cell lung cancer
Weber et al. Expression and functionality of TRPV1 in breast cancer cells
Zanaruddin et al. Four-protein signature accurately predicts lymph node metastasis and survival in oral squamous cell carcinoma
Shiozaki et al. Does positive peritoneal cytology not affect the prognosis for stage I uterine endometrial cancer?: the remaining controversy and review of the literature
Grillo et al. The reliability of endoscopic biopsies in assessing HER2 status in gastric and gastroesophageal junction cancer: a study comparing biopsies with surgical samples
Chern et al. Effects of obesity in rectal cancer surgery
Covens et al. Surgical management of a suspicious adnexal mass: a systematic review
Chen et al. The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis
Li et al. A meta-analysis of the effect of microRNA-34a on the progression and prognosis of gastric cancer.
Cheng et al. Modifications of the AJCC 8th edition staging system for intrahepatic cholangiocarcinoma and proposal for a new staging system by incorporating serum tumor markers
Liu et al. Expression level of NUAK1 in human nasopharyngeal carcinoma and its prognostic significance
Zhong et al. Contribution of nestin positive esophageal squamous cancer cells on malignant proliferation, apoptosis, and poor prognosis
Deng et al. Prognostic value of flotillins (flotillin-1 and flotillin-2) in human cancers: a meta-analysis
Sun et al. Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy
Steen et al. Expression analysis of SOX2 and SOX9 in patients with oral squamous cell carcinoma
RU2014101492A (ru) Способ прогнозирования клинического ответа на химиотерапию у субъекта, имеющего рак
Cheng et al. The prognostic significance of NEK2 in hepatocellular carcinoma: evidence from a meta-analysis and retrospective cohort study
Zhong et al. Association of the intermediate filament nestin with cancer stage: a meta-analysis based on 223 positive/high nestin cases and 460 negative/low case-free controls
Shimokawa et al. TS expression predicts postoperative recurrence in adenocarcinoma of the lung
Xian et al. High APRIL expression correlates with unfavourable survival of gastrointestinal stromal tumour